Meloxicam Prevents Load-Induced Cardiac Hypertrophy in Mice

Author(s): Naoko Shima, Jun-Ichi Suzuki, Masahito Ogawa, Ryo Watanabe, Mitsuaki Isobe

Journal Name: Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Under Re-organization)
Formerly Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents

Volume 12 , Issue 2 , 2012


Background: Although COX-2 inhibitors are known to have adverse effects on myocardial ischemia, the effects of COX-2 inhibitors on cardiovascular diseases are still controversial. Thus, we hypothesized that COX-2 inhibitors affect pressure overloaded myocardial hypertrophy.

Methods and Results: To clarify the role, we used meloxicam in a murine transversal aortic banding (TAC) model. Meloxicam (0.5mg/kg) was given orally twice a day and the mice were sacrificed on day 28 (n=10) after TAC. The drugfree vehicle was used as control (n=7). Echocardiogram revealed that left ventricular (LV) wall thickness was significantly decreased in the meloxicam-treated group compared with the control group. Heart per body weight ratio of the meloxicam-treated group was substantially less than that of the non-treated group. Pathologically, hearts in the meloxicam- treated group showed significantly less LV wall thickness and area of myocardium than those in the control group. RT-PCR showed that COX-2 mRNA levels in hearts increased in the non-treated group, while meloxicam treatment suppressed the levels.

Conclusion: Meloxicam may be useful for preventing pressure overloaded myocardial hypertrophy.

Keywords: Echocardiogram, echocardiograms, histology, heart, blood pressure, COX-2 inhibitors, meloxicam, myocardial hypertrophy, mice, nonsteroidal anti-inflammatory drugs, pathology, pressure overload, transverse aortic constriction, pathology, polymerase chain reaction, wall thickness

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 20 April, 2012
Page: [143 - 146]
Pages: 4
DOI: 10.2174/187152212800389049
Price: $65

Article Metrics

PDF: 9